Tina S. Nova, Ph.D.
Tina S. Nova, Ph.D., began serving as a member of our board of directors in November 2015. Dr. Nova has served as President and Chief Executive Officer of Molecular Stethoscope, Inc., a molecular diagnostics company, since October 2015. Dr. Nova served as Senior Vice President and General Manager of Illumina, Inc.’s oncology business unit from July 2014 to August 2015. From March 2000 to April 2014, Dr. Nova founded and served as a member of the board of directors, President and Chief Executive Officer of Genoptix, Inc., a medical laboratory, which was acquired in 2011 by Novartis Pharmaceuticals Corporation. Dr. Nova also held senior positions with Nanogen, Inc., a molecular diagnostics and biomedical research company; Ligand Pharmaceuticals, Inc., a biopharmaceutical company; and Hybritech, Inc., a monoclonal antibody development company. Dr. Nova has served on the board of directors of Arena Pharmaceuticals, Inc., since September 2004 and as the Chairman of its board of directors since June 2016. Dr. Nova is Vice Chairman of the board of directors of the Rady Pediatric Genomics and Systems Medicine Institute, which is part of Rady Children’s Hospital-San Diego. Dr. Nova received a B.S. degree in Biological Sciences from the University of California, Irvine, and a Ph.D. in Biochemistry from the University of California, Riverside.